Latest News and Press Releases
Want to stay updated on the latest news?
-
REDWOOD CITY, Calif., Nov. 15, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) announced today it will present first-in-human data from its Phase 1 clinical trials of...
-
Ends Quarter with $207 Million Cash Enrollment Complete in Phase 2 Trials for Demcizumab and Tarextumab;On Track for Data in 1H 2017 OncoMed Management to Host Conference Call/Webcast this...
-
REDWOOD CITY, Calif., Oct. 26, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a biopharmaceutical company focused on discovering and developing novel anti-cancer...
-
COPENHAGEN, Denmark and REDWOOD CITY, Calif., Oct. 10, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) today announced the presentation of interim clinical data from its...
-
REDWOOD CITY, Calif., Sept. 29, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) announced today it will present interim data from Phase 1b clinical trials of the company’s Wnt...
-
REDWOOD CITY, Calif., Sept. 01, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical development-stage biopharmaceutical company focused on discovering and developing...
-
REDWOOD CITY, Calif., Aug. 31, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) a clinical development-stage biopharmaceutical company focused on discovering and developing...
-
REDWOOD CITY, Calif., Aug. 30, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical development-stage biopharmaceutical company focused on discovering and developing...
-
REDWOOD CITY, Calif., Aug. 23, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology...
-
REDWOOD CITY, Calif., Aug. 18, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology...